Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment

Investigative Radiology

Volumn 34, Issue 7, 1999, Pages 443-448

  Swan, Suzanne K ^a,b   Lambrecht, Lawrence J ^b   Townsend, Raymond ^c   Davies, Brian E ^d   McCloud, Shirley ^d   Parker, John R ^d   Bensel, Kathleen ^d   LaFrance, Norman D ^d  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b Total Renal Research Inc ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Bracco Research USA   (United States)

Author keywords

Gadolinium; Pharmacokinetics; Renal failure; Safety

Indexed keywords

GADOBENATE DIMEGLUMINE;

ABDOMINAL PAIN; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG SAFETY; ECCHYMOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN TISSUE; INSOMNIA; KIDNEY FAILURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TASTE DISORDER;

EID: 0033004742     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199907000-00001     Document Type: Article

References (10)

1. Uggeri F, Aime S, Anelli PL, et al. Novel Contrast Agents for Magnetic Resonance Imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-Carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-otato(5-)] gadolinate(2-) in a mixture with its enantiomer. Inorg Chem 1995;34:633-642.
2. Davies A. de Haën C. Gadobenic acid dimeglumine salt. Drugs Fut 1991;16:1001-1003.
3. Rosati G, Pirovano G, Spinazzi A. Interim results of Phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29:183-185.
4. WinNonlin V1.1. Pharsight Corp., Apex, NC.
5. SAS Users Guide V6. 11, SAS Institute, Cary, NC.
6. Spinazzi A, Lorusso V, Pirovano G, Davies A, Taroni P. Proceedings of the ISMRM, 1997; Vol II, Abst 933.
7. Yamaoka K, Nakagawa T, Tanaka H. Recirculatory moment analysis of drugs in man: Estimation of extraction ratio and mean cycle time for single systemic and pulmonary circulation. Chem Pharm Bull 1985;33:784-794.
8. LaFrance ND, Parker JR, Lucas TR, et al. Clinical investigation of the safety and pharmacokinetics of gadoteridol injection in renally-impaired patients or patients requiring hemodialysis (abst 287). Third Meeting of the Society for Magnetic Resonance. Nice, France; August 1995.
9. Reinton V, Berg KJ, Svaland MG, Andrew E, Normann PT, Rootwelt K. Pharmacokinetics of gadodiamide injection in patients with moderately impaired renal function. Acad Radiol 1994;1: 56-61.
10. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991;11: 975-979.